NY Times

OCTOBER 9, 2021

Some poorer countries are paying more and waiting longer for the company’s vaccine than the wealthy — if they have access at all.

Vaccination 145

Vaccination Vaccine Drugs Development 145

The Pharma Data

OCTOBER 9, 2021

If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population CMV is one of the most common infections experienced by transplant recipients, with an estimated incidence rate of around 16–56% in solid organ transplant (SOT) recipients and 30–70% in HSCT recipients 3,7 Regulatory submission is based on the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trial of maribavir Maribavir is one of four Wave 1 pipeline new molecular entities that Takeda

Drugs 52

Drugs Genotype Bioavailability Medicine 52

BioTech 365

OCTOBER 9, 2021

Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting — Company maintains focus on advancing … Continue reading →

40

40

The Pharma Data

OCTOBER 9, 2021

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer’s disease (AD) Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous administration in late-stage trials for the treatment of AD Ongoing Phase III GRADUATE programme with gantenerumab is anticipated to deliver a comprehensive data set with expected readout in the second half of 2022.

Antibody 52

Antibody In-Vitro Trials Development 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

BioTech 365

OCTOBER 9, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chilean scientist plans to clean up mining with ‘metal eating’ bacteria.

Scientist 40

Scientist Bacteria Research 40

The Pharma Data

OCTOBER 9, 2021

Application utilizes extrapolation-based strategy across existing breadth of STELARA data in patients living with this chronic inflammatory disease. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

Collaboration Leveraging Neumora’s Precision Neuroscience Platform with Amgen’s deCODE Human Genetics Capabilities to Advance Innovative Medicines for Brain Disease. Amgen and Neumora Therapeutics, a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration to advance neuroscience discovery, development and commercialization.

Genetics 40

Genetics Medicine Development Genome 40

The Pharma Data

OCTOBER 9, 2021

LATTICE-UC proof of concept study did not meet primary nor secondary endpoints. Safety profile of deucravacitinib consistent with other trials and no new safety signals reported. Bristol Myers Squibb. today announced the Phase 2 LATTICE-UC study evaluating deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared to placebo in moderate to severe ulcerative colitis (UC) did not meet the primary efficacy endpoint of clinical remission at Week 12, nor secondary

Trials 52

Trials Immune Response Dermatology Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen and is under Priority Review for patients with asthma in the US. The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

Drugs 52

Drugs Sales Medicine Dermatology 52

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile 1 Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of multiple sclerosis (RMS) patients treated with

Immune Response 52

Immune Response Vaccination Vaccine Medicine 52

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials